MEDVi vs TrimRx vs PlexusDx (2026): Real Cash-Pay GLP-1 Pricing Compared | PlexusDx

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re cross-shopping MEDVi and TrimRx for compounded GLP-1 weight loss, the published prices on each landing page hide the real story. MEDVi advertises $179 for the first month of compounded semaglutide injection then $299/month on refills, with tirzepatide injection from $349/month and tirzepatide tablets from $279/month. TrimRx advertises $299/month for semaglutide unless you commit to a 6-month plan ($191/month) or a 12-month plan ($174/month) paid upfront, with tirzepatide on the same multi-month structure ($283–$316/month). Both are cash-pay, both dispense compounded GLP-1s, and both ask you to either pay a higher month-to-month rate or lock in for a year. This article walks the actual cost math, the medication-source question, the safety considerations on each side, and where PlexusDx Semaglutide Injection, Tirzepatide Injection, and the Microdose GLP-1 Protocol sit relative to both — because the choice between MEDVi, TrimRx, and PlexusDx isn’t about which provider has the loudest landing page. It’s about month-to-month flexibility, total annualized cost, formulation breadth, and whether genetics inform your dose before week one.

MEDVi vs TrimRx vs PlexusDx — quick decision frame

Three pricing models cover this slice of the cash-pay GLP-1 market. MEDVi is a month-to-month compounded platform: $179 month-one promo for semaglutide injection then $299/month on refills, $349/month tirzepatide injection, $279/month tirzepatide tablets, with provider consults, medication, and shipping bundled and a $50/month senior discount for patients 65+. TrimRx is a multi-month compounded platform with steep up-front commitment: $174/month semaglutide on a 12-month plan paid upfront ($2,088 due at signup), $191/month on 6 months, $249/mo on 3 months, or $299/month if you stay month-to-month. Tirzepatide on TrimRx runs $283/month on the 12-month plan and up to $399/month month-to-month. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo, Semaglutide Oral from $249/mo, Tirzepatide Injection at $249/mo, Tirzepatide Oral at $279/mo, and GLP-Squared dual-compound at $249/mo — with no membership, no multi-month upfront commitment, and the optional Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after the first month) that anchors dose decisions to the patient’s GIPR, GLP1R, FTO, MC4R, and TCF7L2 variants instead of population averages.

The real annual cost: MEDVi vs TrimRx vs PlexusDx

For a cash-pay patient on semaglutide injection, the year-one math runs like this. MEDVi’s month-one promo plus 11 refills totals roughly $3,468/year ($179 + $299 × 11). TrimRx’s month-to-month rate runs $3,588/year, the 6-month plan annualizes to $2,292, and the 12-month plan annualizes to $2,088 — but the 12-month plan is paid upfront, so the entire $2,088 is due at signup with no refund for unused months in most cases. PlexusDx Semaglutide Injection runs $2,148–$2,748/year ($149/mo) billed monthly with no upfront commitment, while the Microdose GLP-1 Protocol stays at $1,548/year ($129/mo flat) for patients who want a starter-dose oral or sublingual delivery. On tirzepatide, MEDVi runs ~$4,188/year (~$349/mo), TrimRx ranges from $3,396/year (12-month upfront at $283) to $4,788/year (month-to-month at $399), and PlexusDx Tirzepatide Injection runs $2,748–$3,708/year billed monthly. Add $99 for the Precision Peptide Genetic Test as an add-on after month one and the genetic-baseline-included totals on PlexusDx still come in below MEDVi at the entry tier and competitive with TrimRx’s 12-month upfront plans — without locking up a year of cash.

Compounded vs branded — what each platform actually dispenses

All three platforms dispense compounded semaglutide and tirzepatide — formulations prepared by licensed U.S. compounding pharmacies under U.S. compounding regulations. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. None of MEDVi, TrimRx, or PlexusDx dispenses the FDA-approved branded products directly. MEDVi states it works with “multiple USA certified pharmacies” and third-party reporting names Belmar Pharma Solutions and Beluga Health among its partners. TrimRx does not publicly name its compounding pharmacy partners, which several BBB and Trustpilot reviewers cite as a friction point. PlexusDx uses licensed U.S. compounding pharmacies and provides four delivery formats — weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound stacks via GLP-Squared — so a patient who can’t tolerate weekly injections has more than one re-titration path inside the same provider relationship.

Safety, side effects, and clinical oversight

All three programs prescribe medications in the GLP-1 receptor agonist class, plus tirzepatide which is a GIP/GLP-1 dual agonist. The labeled side-effect profile is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies, which means a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication on every platform in this comparison. The clinical-oversight question is where the three differ most. MEDVi routes through the OpenLoop Health licensed-provider network with 24/7 messaging and is LegitScript-certified. TrimRx routes through licensed telehealth providers but is not LegitScript-certified and does not publicly name its provider network or pharmacy partners. PlexusDx uses licensed U.S. providers and pharmacies and adds a stratification step neither MEDVi nor TrimRx performs — clinical review of the patient’s genetic test before titration when the test is included in the protocol pathway.

Why genetics matter before you choose a GLP-1 provider

GLP-1 response varies meaningfully across patients. Variants in GIPR (the GIP receptor that tirzepatide engages alongside GLP-1), GLP1R (the GLP-1 receptor itself), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 unique genes and 57 genetic variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician can decide whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit a given patient’s biology before week one. Neither MEDVi nor TrimRx offers a genetic baseline as part of the intake. Both start from a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors the same conversation to a measurable genetic baseline, available standalone for $298 or as a $99 add-on after the first month on any protocol.

Cancellation, refunds, and the fine print

This is where MEDVi and TrimRx diverge sharply, and where the multi-month-upfront model deserves a careful read. MEDVi’s published policy states no refund is issued once a billing cycle has been charged; to avoid the next charge you must cancel at least 72 hours before your billing date, and standard cancellations don’t entitle you to a refund for the current period. TrimRx’s month-to-month plan can be cancelled before the next billing cycle, but the 6-month and 12-month plans are billed upfront — reviewers on Trustpilot and BBB have flagged friction around prorated refunds and partial cancellations on those upfront plans. PlexusDx is cash-pay, no membership, billed monthly; there is no upfront 6- or 12-month commitment to unwind, and patients can pause or switch protocols (Microdose, Semaglutide Injection, Tirzepatide Injection, GLP-Squared) without losing pre-paid months. PlexusDx does not accept insurance and does not run as a membership — the published per-protocol price is what the patient pays, and the genetic test is a one-time cost rather than a recurring subscription.

Formulation breadth — injection, oral, microdose, dual-compound

If a patient can’t tolerate weekly injections, struggles with high-dose nausea, or wants a non-injection starter, the three platforms offer different exits. MEDVi offers semaglutide injection or semaglutide tablets, tirzepatide injection or tirzepatide tablets — four SKUs across two molecules. TrimRx offers semaglutide injection and tirzepatide injection only as of the price card cited in the comparison; tablet and microdose paths are not advertised on the standard plans. PlexusDx offers six distinct protocols across four mechanism classes: Microdose GLP-1 Protocol (capsule, troche, lozenge, sublingual variants at $129/mo flat), Semaglutide Oral (3mg–24mg daily across six dose levels from $249/mo), Semaglutide Injection (0.25mg–2.0mg weekly across five dose levels at $149/mo), Tirzepatide Injection (2.5mg–15mg weekly across six dose levels at $249/mo), Tirzepatide Oral (5mg–25mg daily across seven dose levels at $279/mo), and GLP-Squared (compounded semaglutide + tirzepatide dual-compound across six provider-titrated dose pairs at $249/mo). The breadth matters because most patients who fail one delivery format don’t fail every format — switching from weekly injection to daily oral or to microdose is a re-titration conversation, not a provider switch.

Which one fits — a five-question decision frame

Question 1: Is your insurance going to cover Wegovy or Zepbound at a low copay? If yes, branded FDA-approved medication through your insurance plan is almost always cheaper than any cash-pay compounded route. Question 2: Are you cash-pay, with no GLP-1 coverage, and price is the dominant factor on a per-month basis? Compare TrimRx’s 12-month upfront ($174/mo semaglutide, $283/mo tirzepatide) against PlexusDx Semaglutide Injection ($149/mo monthly billing) and the Microdose GLP-1 Protocol at $129/mo flat. Question 3: Do you want month-to-month flexibility without paying a year upfront? PlexusDx and MEDVi both bill monthly; TrimRx month-to-month is the most expensive option in the comparison. Question 4: Are you 65 or older? MEDVi’s $50/month senior discount is unique in this comparison. Question 5: Do you want a genetic baseline informing dose and titration before the first injection? PlexusDx is the only option in this comparison that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

Is MEDVi legit and how does it compare to PlexusDx on credibility?

MEDVi is LegitScript-certified, has roughly 11,498 Trustpilot reviews at 4.4/5, and uses the OpenLoop Health provider network. PlexusDx uses licensed U.S. providers and licensed U.S. compounding pharmacies, is cash-pay with no membership, and adds a genetic-baseline step (Precision Peptide Genetic Test) that MEDVi does not perform. Both are legitimate cash-pay compounded GLP-1 platforms; they differ on whether dose decisions start from population averages or from your own variants.

Is TrimRx legit and is the 12-month upfront plan worth it?

TrimRx is an operating telehealth provider with roughly 635 Trustpilot reviews at ~3.4/5 and is not LegitScript-certified. The 12-month upfront plan ($174/mo semaglutide) requires roughly $2,088 due at signup and most cancellations on that tier do not produce a full prorated refund. PlexusDx Semaglutide Injection at $149/mo is billed monthly without an upfront commitment, which is a meaningfully different financial risk profile.

Are compounded GLP-1 medications safe?

Compounded semaglutide and tirzepatide are prepared by licensed U.S. compounding pharmacies and are not FDA-approved finished drug products. The active ingredients are the same molecules found in Wegovy, Ozempic, Mounjaro, and Zepbound, but the regulatory framework is different. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies. Use a licensed provider, confirm the pharmacy is a U.S. compounding pharmacy, and discuss any decision with a clinician.

Does either MEDVi or TrimRx accept insurance?

No. Both are cash-pay only, and so is PlexusDx. If your plan covers Wegovy, Ozempic, or Zepbound, the FDA-approved branded medication through your insurance is almost always cheaper than any cash-pay compounded option. Check your formulary first.

What is the cheapest way to start a GLP-1 in 2026 if I have no insurance coverage?

If insurance is not in play, the lowest entry points in this comparison are PlexusDx Microdose GLP-1 Protocol at $129/mo flat (oral or sublingual delivery), MEDVi’s $179 first-month promo on semaglutide injection (then $299/mo), and TrimRx’s 12-month upfront at $174/mo (paid as ~$2,088 at signup). The right choice depends on whether you want flexibility, a senior discount, or a genetic-informed dose — not just the per-month number.

What about side effects and stopping the medication?

Common side effects across all three providers are nausea, vomiting, diarrhea, constipation, abdominal pain, and headache — the labeled GLP-1 profile. Pancreatitis, gallbladder disease, and acute kidney injury are less common but documented. Don’t stop GLP-1 medication abruptly without a plan; the gap can cause rebound appetite, and any new provider will likely restart you at a lower dose. Discuss any stop, switch, or dose change with the prescribing clinician.

Can I switch from MEDVi or TrimRx to PlexusDx mid-treatment?

Yes. There are no exclusivity agreements between cash-pay GLP-1 providers. Tell the new provider what medication, dose, and titration step you were on so they can manage the transition appropriately. PlexusDx adds a genetic test pathway via the Precision Peptide Genetic Test ($298 standalone or $99 add-on after the first month) that can inform whether you should continue on semaglutide, switch to tirzepatide, or move to the dual-compound GLP-Squared protocol.

Related reading on PlexusDx

Related reading on PlexusDx: GLP-1 Cost, Semaglutide Cost, Tirzepatide Costs, Cheapest GLP-1.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing for MEDVi and TrimRx is based on each provider’s published rates as of April 2026; actual costs may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.